187 related articles for article (PubMed ID: 29771164)
21. Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach.
Klimant E; Wright H; Rubin D; Seely D; Markman M
Curr Oncol; 2018 Apr; 25(2):139-148. PubMed ID: 29719430
[TBL] [Abstract][Full Text] [Related]
22. All's well that ends well? Quality of life and physical symptom clusters in long-term cancer survivors across cancer types.
Zucca AC; Boyes AW; Linden W; Girgis A
J Pain Symptom Manage; 2012 Apr; 43(4):720-31. PubMed ID: 22277904
[TBL] [Abstract][Full Text] [Related]
23. Final report of the safety assessment of L-Ascorbic Acid, Calcium Ascorbate, Magnesium Ascorbate, Magnesium Ascorbyl Phosphate, Sodium Ascorbate, and Sodium Ascorbyl Phosphate as used in cosmetics.
Elmore AR
Int J Toxicol; 2005; 24 Suppl 2():51-111. PubMed ID: 16154915
[TBL] [Abstract][Full Text] [Related]
24. A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.
Martel ML; Klein LR; Rivard RL; Cole JB
Acad Emerg Med; 2016 Jan; 23(1):29-35. PubMed ID: 26720055
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
27. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models.
Chen P; Stone J; Sullivan G; Drisko JA; Chen Q
Free Radic Biol Med; 2011 Aug; 51(3):681-7. PubMed ID: 21672627
[TBL] [Abstract][Full Text] [Related]
28. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.
Hoffer LJ; Levine M; Assouline S; Melnychuk D; Padayatty SJ; Rosadiuk K; Rousseau C; Robitaille L; Miller WH
Ann Oncol; 2008 Nov; 19(11):1969-74. PubMed ID: 18544557
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
30. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer.
Ellis PM; Chu QS; Leighl N; Laurie SA; Fritsch H; Gaschler-Markefski B; Gyorffy S; Munzert G
Clin Lung Cancer; 2013 Jan; 14(1):19-27. PubMed ID: 22658814
[TBL] [Abstract][Full Text] [Related]
31. [Tropisetron hydrochloride in preventing and treating chemotherapy-induced nausea and vomiting: a phase II, randomized, multicenter, double-blinded, comparative clinical trial].
Zhang WD; Wang XW; Chen ZD; Qin FZ; Shu YQ; Pan LX; Zhang MH
Ai Zheng; 2007 Aug; 26(8):870-3. PubMed ID: 17697550
[TBL] [Abstract][Full Text] [Related]
32. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].
Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027
[TBL] [Abstract][Full Text] [Related]
33. Examining patterns of multivariate, longitudinal symptom experiences among older adults with type 2 diabetes and cancer via cluster analysis.
Hershey DS; Pierce SJ
Eur J Oncol Nurs; 2015 Dec; 19(6):716-23. PubMed ID: 26051076
[TBL] [Abstract][Full Text] [Related]
34. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
35. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
[TBL] [Abstract][Full Text] [Related]
36. Intravenous ascorbic acid: protocol for its application and use.
Riordan HD; Hunninghake RB; Riordan NH; Jackson JJ; Meng X; Taylor P; Casciari JJ; González MJ; Miranda-Massari JR; Mora EM; Rosario N; Rivera A
P R Health Sci J; 2003 Sep; 22(3):287-90. PubMed ID: 14619456
[TBL] [Abstract][Full Text] [Related]
37. Brief Report: Stability and Chemical Characteristics of Injectable Ascorbic Acid for Patients With Cancer.
Monti DA; Bazzan AJ; Zabrecky G; Newberg AB
Altern Ther Health Med; 2019 Mar; 25(2):42-45. PubMed ID: 28987078
[TBL] [Abstract][Full Text] [Related]
38. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects.
Padayatty SJ; Sun AY; Chen Q; Espey MG; Drisko J; Levine M
PLoS One; 2010 Jul; 5(7):e11414. PubMed ID: 20628650
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
40. Effects of High Doses of Vitamin C on Cancer Patients in Singapore: Nine Cases.
Raymond YC; Glenda CS; Meng LK
Integr Cancer Ther; 2016 Jun; 15(2):197-204. PubMed ID: 26679971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
